Template:Androgen/anabolic steroid dosages for breast cancer
Appearance
Route | Medication | Form | Dosage | Refs |
---|---|---|---|---|
Oral | Methyltestosterone | Tablet | 30–200 mg/day | [1][2][3][4] |
Fluoxymesterone | Tablet | 10–40 mg 3x/day | [1][5][6][7] | |
Calusterone | Tablet | 40–80 mg 4x/day | [1][7] | |
Normethandrone | Tablet | 40 mg/day | [2] | |
Buccal | Methyltestosterone | Tablet | 25–100 mg/day | [4] |
Injection (IM or SC ) | Testosterone propionate | Oil solution | 50–100 mg 3x/week | [1][2][8][6][7] |
Testosterone enanthate | Oil solution | 200–400 mg 1x/2–4 weeks | [9][10] | |
Testosterone cypionate | Oil solution | 200–400 mg 1x/2–4 weeks | [10][11] | |
Mixed testosterone esters | Oil solution | 250 mg 1x/week | [6] | |
Methandriol | Aqueous suspension | 100 mg 3x/week | [8][11] | |
Androstanolone (DHT) | Aqueous suspension | 300 mg 3x/week | [2][8][12][11] | |
Drostanolone propionate | Oil solution | 100 mg 1–3x/week | [1][2][7] | |
Metenolone enanthate | Oil solution | 400 mg 3x/week | [7] | |
Nandrolone decanoate | Oil solution | 50–100 mg 1x/1–3 weeks | [13][14][15] | |
Nandrolone phenylpropionate | Oil solution | 50–100 mg/week | [16][7] | |
Note: Dosages are not necessarily equivalent. |
See also
- Template:Estrogen dosages for breast cancer
- Template:Estrogen dosages for prostate cancer
- Template:Androgen replacement therapy formulations and dosages used in women
- Template:Clinical dosage ranges of oral and injectable androgens and anabolic steroids
References
- ^ a b c d e Lupulescu A (24 October 1990). "Hormones and Hormonotherapy". Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 33–90. ISBN 978-0-8493-5973-6.
- ^ a b c d e Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli, David G. Johns (eds.). Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8.
- ^ "Android® C-III" (PDF). Valeant Pharmaceuticals North America. U.S. Food and Drug Administration.
- ^ a b Ebadi M (31 October 2007). Desk Reference of Clinical Pharmacology. CRC Press. pp. 434–. ISBN 978-1-4200-4744-8.
- ^ Perry MC (2008). The Chemotherapy Source Book. Lippincott Williams & Wilkins. pp. 369–. ISBN 978-0-7817-7328-7.
- ^ a b c Martz G (13 March 2013). Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms. Springer-Verlag. pp. 39–. ISBN 978-3-642-86282-3.
- ^ a b c d e f Brotherton J (1976). Sex Hormone Pharmacology. Academic Press. p. 437. ISBN 978-0-12-137250-7.
- ^ a b c Council on Drugs (1960). "Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients". JAMA. 172 (12): 1271–83. doi:10.1001/jama.1960.03020120049010.
- ^ "DELATESTRYL® CIII (Testosterone Enanthate Injection, USP)" (PDF). U.S Food and Drug Administration.
- ^ a b American Medical Association. Division of Drugs; American Society for Clinical Pharmacology and Therapeutics (1983). "Androgens and Anabolic Steroids". AMA Drug Evaluations. American Medical Association. pp. 913–930. ISBN 978-0-89970-160-8.
TESTOSTERONE CYPIONATE [Andro-Cyp, Depo-Testosterone, T-Ionate-P.A.] TESTOSTERONE ENANTHATE [Andryl, Delatestryl] These long-acting, potent esters of testosterone can maintain the testosterone level within the normal range in males for two to four weeks. [...] For metastatic breast carcinoma in women, 200 to 400 mg every two or more weeks.
- ^ a b c Green RB, Sethi RS, Lindner HH (July 1964). "Treatment of advanced carcinoma of the breast: Progress in therapy during the past decade". Am. J. Surg. 108: 107–21. doi:10.1016/0002-9610(64)90094-7. PMID 14182428.
- ^ Segaloff A, Horwitt BN, Carabasi RA, Murison PJ, Schlosser JV (1955). "Hormonal therapy in cancer of the breast. VIII. The effect of dihydrotestosterone (androstanolone) on clinical course and hormonal excretion". Cancer. 8 (1): 82–86. doi:10.1002/1097-0142(1955)8:1<82::AID-CNCR2820080110>3.0.CO;2-R. PMID 13231036. S2CID 10089663.
- ^ "DECA-DURABOLIN (nandrolone decanoate)" (PDF). Archived from the original (PDF) on 2019-03-09.
- ^ "DECA-DURABOLIN" (PDF). New Zealand Data Sheet. Archived from the original (PDF) on 2018-01-28.
- ^ Shorr RI (11 April 2007). Drugs for the Geriatric Patient E-Book. Elsevier Health Sciences. pp. 844–. ISBN 978-1-4377-1035-9.
- ^ McKone WL (11 November 2013). Osteopathic Athletic Health Care: Principles and practice. Springer. pp. 125–. ISBN 978-1-4899-3067-5.